Facebook Pixel Code
About Sickkids
About SickKids

Valerie Waters, MD, MSc

The Hospital for Sick Children
Staff Physician
Infectious Diseases

Research Institute
Associate Scientist
Translational Medicine

University of Toronto
Associate Professor
Department of Paediatrics

Phone: 416-813-7654 ext. 204541
Fax: 416-813-8404
Email: valerie.waters@sickkids.ca

Research Interests

My research program is focused on the investigation of the epidemiology and treatment of multi-drug resistant bacterial pathogens causing lung infections in patients with cystic fibrosis (CF). I am particularly interested in the way these organisms grow as communities of bacteria known as biofilms, which are associated with increased antimicrobial resistance. My lab has developed novel biofilms models to test the efficacy of compounds against Pseudomonas aeruginosa biofilms, in the context of host factors and other microbes. We are currently studying the interaction between Staphylococcus aureus and P. aeruginosa grown within biofilms in the context of failure of early eradication treatment of P. aeruginosa in children with CF. In addition, we also investigate the effects of antibiotic treatment of pulmonary exacerbations in CF and are conducting a clinical trial of oral prednisone as an adjuvant therapy in CF patients with pulmonary exacerbations.  

External Funding

Agency: US Cystic Fibrosis Foundation
Time Period: 2018-2020
Title of project: Early Pseudomonas aeruginosa infection in cystic fibrosis
Investigator status: Principal Investigator

Agency: CIHR
Time Period: 2017-2020
Title of project: Next-Generation Antimicrobial Diagnostics: Speed and Precision via Whole Genome Sequencing
Investigator status: Co-Investigator

Agency: Gilead Sciences Inc.
Time Period: 2016-2019
Title of project: The effect of Staphylococcus aureus on the establishment of Pseudomonas aeruginosa biofilm infections in cystic fibrosis
Investigator status: Principal investigator

Agency: Cystic Fibrosis Canada
Time Period: 2017-2020
Title of project: PIPE – CF Biomarker Study
Investigator status: Co-Investigator

Agency: Cystic Fibrosis Canada
Time Period: 2016-2019
Title of project: Randomized controlled trial of prednisone in CF pulmonary exacerbations (PIPE Study)
Investigator status: Principal investigator


Beaudoin T, Yau YCW, Stapleton PJ, Gong, Y, Wang PW, Guttman DS, Waters V. Staphylococcus aureus interaction with Pseudomonas aeruginosa biofilm enhances tobramycin resistance. NPJ Biofilms and Microbiomes Oct 17 2017. [Epub ahead of print]. 

Somayaji R, Stanojevic S, Tullis E, Stephenson A, Ratjen F, Waters V. Clinical outcomes associated with Achromobacter species infection in patients with cystic fibrosis.  Ann Am Thorac Soc. Ann Am Thorac Soc. 2017 Apr 13. [Epub ahead of print] 

Waters V, Yau Y, Beaudoin T, Wettlaufer J, Tom SK, McDonald N, Rizvi L, Klingel M, Ratjen F, Tullis E. Pilot trial of tobramycin inhalation powder in cystic fibrosis patients with chronic Burkholderia cepacia complex infection. J Cyst Fibros. 2017 Mar 2. [Epub ahead of print]. 

Blanchard A, Horton E, Stanojevic S, Taylor L, Waters V, Ratjen F. Effectiveness of a stepwise Pseudomonas aeruginosa eradication protocol in children with cystic fibrosis. J Cyst Fibros. 2017 Feb 9. [Epub ahead of print]. 

Wettlaufer J, Klingel M, Yau Y, Stanojevic S, Tullis E, Ratjen F, Waters V. Longitudinal study of Stenotrophomonas maltophilia antibody levels and outcomes in cystic fibrosis patients. J Cyst Fibros. 2017 Jan;16(1):58-63. 

Beaudoin T, Waters V. Invasive infections with biofilm formation: selection of antimicrobials and role of prolonged antibiotic therapy. Pediatr Infect Dis J. 2016 Jun;35(6):695-7. 

Vidya P, Smith L, Beaudoin T, Yau YCW, Clark S, Coburn B, Guttman D, Hwang DM, Waters V. Chronic infection phenotypes of Pseudomonas aeruginosa are associated with failure of eradication in children with cystic fibrosis. Eur J Clin Microbiol Infect Dis. 2016 Jan;35(1):67-74.